CompletedNCT01244490
Extended-Release Guanfacine for Children and Teens With ADHD
About this title
Read the official source — NCT01244490This study evaluated the safety and effectiveness of Extended-release Guanfacine Hydrochloride for people with ADHD.
Medication studyAges 6–17Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Extended-release Guanfacine Hydrochloride for people with ADHD.
Who was this study for?
Listed age limits: 6 years to 17 years.
- Listed locations
- San Diego and 65 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: January 17, 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 338
- Sponsor
- Shire
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Canada, ...
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT01244490
- Official title
Show the full official title
A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedSan Diego, United States · Maitland, United States · Atlanta, United States
60 more locations
- Overland Park, United States
- Rochester Hills, United States
- Omaha, United States
- Fargo, United States
- Memphis, United States
- Houston, United States
- Lake Jackson, United States
- Herndon, United States
- Graz, Austria
- Vienna, Austria
- Niagara Falls, Canada
- Ottawa, Canada
- Amiens, France
- Bordeaux, France
- Chartres, France
- Hagen, Germany
- Achim, Germany
- Berlin, Germany
- Dresden, Germany
- Düsseldorf, Germany
- Fulda, Germany
- Hamburg, Germany
- Hüttenberg, Germany
- Mainz, Germany
- Mannheim, Germany
- Schwerin, Germany
- Dublin, Ireland
- Pisa, Italy
- Rome, Italy
- Verona, Italy
- Torun, Poland
- Wroclaw, Poland
- Warsaw, Poland
- Gdansk, Poland
- Cluj-Napoca, Romania
- Timișoara, Romania
- Bucharest, Romania
- Iași, Romania
- Terrassa, Spain
- Barcelona, Spain
- Donostia / San Sebastian, Spain
- Málaga, Spain
- Santa Cruz de Tenerife, Spain
- Santander, Spain
- Valencia, Spain
- Gothenburg, Sweden
- Mölnlycke, Sweden
- Varberg, Sweden
- Kharkiv, Ukraine
- Donetsk, Ukraine
- Kherson, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Vinnytsia, Ukraine
- Kirkcaldy, United Kingdom
- Great Yarmouth, United Kingdom
- Ashurst, United Kingdom
- Horsham, United Kingdom
- Wigan, United Kingdom
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Extended-release Guanfacine Hydrochloride for people with ADHD.
Who is behind this study?
The study sponsor is Shire.
Did this study involve medication?
Yes. The study involved medication, including Extended-release Guanfacine Hydrochloride, Atomoxetine Hydrochloride and Placebo Comparator.
Who was this study for?
Listed age limits: 6 years to 17 years.
